

Callitas Health Inc

16:05 28 May 2019

Callitas Health appoints former interim CEO as M&A consultant

Callitas Health Inc (CSE:LILY) (OTCMKTS:MPHMF) (FWB:T3F3), the clinical-stage pharmaceutical company, named former interim CEO Brian Keane capital markets and merger and acquisitions consultant.

Keane is currently CEO of Qualified Capital Consultants and co-founder of 420 Acquisitions LLC. He also served as founding director at 1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF).

He also brings a wealth of M&A experience from his time at Deutsche Bank (NYSE:DB), Rodman and Renshaw, Ladenburg Thalmann & Co, Techvest LLC and Yorkville Advisors.

READ: Callitas Health wins notice of allowance from US Patent and Trademark Office in regards to patent for new cannabis 'candy'

"We are proud to welcome Brian back to the Callitas team," CEO James Thompson said. "As prior interim CEO, Brian is familiar with our patented delivery technology, as well as the multiple assets that are owned by the company that will be evaluated for monetization as we expand into the legal cannabis market."

Callitas is a Cincinnati-based company focused on developing technologies to address weight management, female sexual health and wellness, and cannabis delivery.


Shares were unchanged on the CSE at C\$10 and at \$US0.09 on OTC markets.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Market Cap: \$0.00

1 Year Share Price Graph



Share Information

Code: LILY

Listing: CSE

52 week High Low
0.12 0.09

Sector: Pharma & Biotech

Website: www.callitas.com

Company Synopsis:

Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers, shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others. Our number one goal is helping people by bringing products to market that improve quality of life.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).